Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential Transcriptional Landscape of Vero Cells During Dengue Virus 2 Infection in the Presence of Sinococuline.

Microorganisms·2025
Same author

Epidemiologic and Genomic Characterization of an Outbreak of Rift Valley Fever Among Humans and Dairy Cattle in Northern Tanzania.

The Journal of infectious diseases·2024
Same author

Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines.

Vaccines·2023
Same author

Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice.

Frontiers in immunology·2023
Same author

Sinococuline, a bioactive compound of Cocculus hirsutus has potent anti-dengue activity.

Scientific reports·2023
Same author

Presence of Recombinant Bat Coronavirus GCCDC1 in Cambodian Bats.

Viruses·2022

Related Experiment Video

Updated: Jun 16, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Adenovirus-vectored vaccines.

Tanu Chawla1, Navin Khanna, Sathyamangalam Swaminathan

  • 1International Centre for Genetic Engineering & Biotechnology, Recombinant Gene Products Group, PO Box 10504, Aruna Asaf Ali Marg, New Delhi-110067, India.

Expert Opinion on Therapeutic Patents
|February 11, 2010
PubMed
Summary

Engineered adenoviruses show promise as vaccine vectors, but their immunogenicity presents challenges. Research is ongoing to develop alternative adenovirus vectors and strategies for improved vaccine efficacy.

More Related Videos

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Related Experiment Videos

Last Updated: Jun 16, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • Engineered adenoviruses are increasingly investigated as vaccine vectors for prophylaxis and therapy.
  • Preclinical success with human adenovirus vectors has led to numerous clinical trials.

Purpose of the Study:

  • To review the current landscape of adenovirus-based vaccine vector development.
  • To analyze patent literature from 2000 onwards concerning adenovirus vaccine vectors.

Main Methods:

  • Systematic review of patent literature published since 2000.
  • Focus on adenovirus vectors for both infectious and non-infectious diseases.

Main Results:

  • Adenovirus vectors, particularly human adenoviruses, face limitations due to immunogenicity.
  • These limitations impact the broad utility of current adenovirus-vectored vaccines.

Conclusions:

  • Significant efforts are underway to develop alternative adenovirus vectors and novel strategies.
  • Each alternative vector and strategy presents unique benefits and drawbacks requiring further investigation.